Focal Therapy is an Option for the Majority of Localised Prostate Cancers: A Histopathological Study of Contemporary UK Radical Prostatectomies

Abstract

Objectives:

Focal therapy for prostate cancer offers a management option intermediate between active surveillance and radical therapy for small volume, low grade localised prostate cancer. We studied a series of UK radical prostatectomies (RP) performed for organ-confined prostate cancer to identify the proportion of cases potentially suitable for pure lesion only focal therapy (PLFT) or focal hemi-gland ablation (FHA).

Methods:

The pathological features of 309 RP specimens were studied. Patients were grouped into the following categories: group A: unifocal cancer; group B: multifocal disease where only the index cancer was significant (Epstein's criteria); group C: unilateral multifocal significant disease; group D: bilateral multifocal significant disease.

Results:

56% (172) patients were candidates for PLFT, including 70 group A cases plus 102 group B cases. Group C comprised 4% (11) cases who are candidates for FHA. Thus 60% (183) cases were candidates for either PLFT or FHA.

Conclusions:

A significant number of patients are potential candidates for focal therapy in this RP series. We encourage prospective clinical trials investigating the oncological safety and outcomes of focal therapy in treating low and intermediate risk localised prostate cancer.

Keywords

Focal therapy Prostate cancer Hemigland ablation

Get full access to this article

View all access options for this article.

References

Brewster

. Low risk prostate cancer. Are we ready to tell the patients that active r, surveillance is the preferred option? BJU 2008; 102 (8): 923–6.

Fowler

Jr Barry

Lu-Yao

Roma

Wasson

Wennberg

. Patient reported complications and followup treatment after radical proatectomy. The National Medicare Experience 1988–90 (updated June 1993). Urology 1993; 42: 622–9.

Walsh

Donker

. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol 1982; 128: 492.

Eggener

Salomon

Scardino

De la Rosette

Polascik

Brewster

. Focal therapy for prostate cancer: possibilities and limitations. Eur Urol 2010; 58: 57–64.

D'Amico

Whitttington

Malkowicz

Schultz

Blank

Broderick

GAT

Biochemical outcome after radical prostatectomy, external beam radiotherapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969–74.

Epstein

Walsh

Carmichael

Brendler

. Pathologic and clinical findings to predict tumour extension of non-palpable (stage T1c) prostate cancer. JAMA 1994; 2 (271(5)): 368–74.

Bostwick

Waters

Farley

Meiers

Rukstalis

Cavanaugh

Group consensus reports from the consensus conference on focal treatment of prostatic carcinoma, celebration, Florida, Feb 24, 2006. Urology 2007; 70 (6 (Suppl.)): 42–4.

Meiers

Walters

Bostwick

. Preoperative prediction of multifocal prostate cancer and application of focal therapy. Review 2007. Urology 2007; 70: S3–81.

Arora

Koch

Eble

Ulbright

Cheng

. Heterogeneity of gleason grade in multifocal adenocarcinoma of the prostate. Cancer 2004; 100: 2362–6.

10.

Ohori

Eastham M

Koh

Kuroiwa

Slawin

Wheeler

Is focal therapy reasonable in patients with early stage prostate cancer (CAP)—an analysis of radical prostatectomy specimens. J Urol 2006; 175 (Suppl.): 507 [abstract].

11.

Song

Kim

Ahn

Choi

. Pathologic characteristics of prostate adenocarcinoma. A mapping analysis of Korean patients. Prostate Cancer Prostatic Dis 2003; 6: 143–7.

12.

Cheng

Jones

Pan

Barabarn

Eble

Koch

. Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole mount prostatectomy specimens. Mod Pathol 2005; 18: 1022–6.

13.

Mouraviev

Mayes

Sun

Madden

Moul

Polascik

. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer 2007; 110: 906–10.

14.

Yoon

Wang

Osunkoya

Lane

Partin

Epstein

. Residual tumor potentially left behind after local ablation therapy in prostate adenocarcinoma. J Urol 2008; 179: 2203–6.

15.

Noguchi

Stamey

McNeal

Nolley

. Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers. J Urol 2003; 170: 459–63.

16.

Makarov

Sanderson

Parting

Epstein

. Gleason score 7 prostate cancer on needle biopsy: Is the prognostic difference in gleason scores 4+3 and 3+4 independent of number of involved cores? J Urol 2002; 167: 2440–2.

17.

Groll

Fleshner

Sugar

Ezer

Klotz

. Clinical significance of biopsy-derived primary Gleason score among radical prostatectomy condidates with Gleason 7 tumors. Urology 2002; 59: 551–4.

18.

Johnstone

Rossi

Jani

Master

. Insignificant prostate cancer on biopsy: pathologic results from subsequent radical prostatectomy. Prostate Cancer Prostatic Dis 2007; 10: 237–41.

19.

Furuno

Demura

Kaneta

Gotoda

Muraoka

Sato

Difference of cancer core distribution between first and repeat biopsy: in patients diagnosed by extensive transperineal ultrasound guided template prostate biopsy. Prostate 2004; 58: 76–81.

20.

Onik

. Barzell: Transperineal 3D mapping biopsy of the prostate: an essential tool in selecting patients for focal prostate cancer therapy. Urol Oncol 2008; 26 (5): 506–10.

21.

Muto

Yoshii

Saito

Kamiyama

Ide

Horie

. Focal therapy with high intensity—focused ultrasound in the treatment of localized prostate cancer. Jpn J Clin Oncol 2008; 38: 192–9.

22.

Babian

Donnelly

Bahn

Baust

Dineen

Ellis

Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol 2008; 180 (5): 1993–2004.

23.

Polascik

Tsivian

. Focal therapy for prostate cancer. Current Urology Rep 2010; 11: 147–51.